Better Health for All

Bristol-Myers Squibb's health equity programs show minimal funding, with a target investment of $150 million by 2025 representing 0.33% of its 2023 pharmaceutical revenue

, and current grants totaling $1.8 million. However, the company's core products deliver substantial health benefits, targeting serious diseases like cancer and cardiovascular conditions , with 4 products on the WHO Essential Medicines List. It demonstrates strong vulnerable reach through its ASPIRE strategy, aiming to reach over 200,000 patients annually in 85 low- and middle-income countries and 32 least developed countries by 2033 , complemented by a commitment not to enforce patents in these regions , and collaboration with the ATOM Coalition. The company also exhibits comprehensive pharma patent flexibility with non-exclusive voluntary licensing for two drugs. For price accessibility, it provides substantial patient support programs, including $2.5 billion for commercially insured patients (2019-2023) and over $4 billion in medicine donations (2023) , alongside an average discount rate of 46% of gross sales ; however, the company has also challenged the U.S. Medicare drug price negotiation program. Risk transparency is excellent, with disclosures of commitments, targets, patent information via Pat-INFORMED , and proactive recall notifications. Its safety record is strong, with no regulatory violations found in 2025 , following a single voluntary recall in 2017 with no reported injuries. Healthcare workforce support and education are basic, limited to providing healthcare professional education and training in cancer care and prevention.

Fair Money & Economic Opportunity

Bristol-Myers Squibb is a biopharmaceutical company, and its core business does not involve offering lending, deposit, or other financial services to consumers. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to its operations in the context defined by the rubric. The company does not offer lending or deposit services, consumer credit products, high-cost financial products, or operate financial service access points. It is not regulated as a lender and does not generate or manage customer finance data. While the company engages in significant health equity initiatives, such as expanding access to medicines in over 80 low- and middle-income countries

and committing $300 million to health equity efforts, these activities do not directly align with the financial services context of the KPIs.

Fair Pay & Worker Respect

Bristol-Myers Squibb's CEO-to-median-employee pay ratio for 2024 was 117:1.

The company reported a median gender pay gap of 14.5% in the UK according to its 2025 report, indicating women earn 85.5% of men's pay. Employee satisfaction in the UK was 92% in 2024, and the company was ranked 8th in the Great Place to Work UK’s Best Workplaces 2024 Super Large Category, and 3rd in the Best Workplaces for Women Super Large Category. In 2023, BMS was cited by the Occupational Safety and Health Administration (OSHA) for a workplace safety or health violation, resulting in a penalty of $80,655.

Fair Trade & Ethical Sourcing

Bristol Myers Squibb Canada reported zero substantiated forced or child labor findings in its May 2024 annual report.

Regarding supplier diversity, in 2020, the company's Diverse Business Enterprise spend constituted 13.59% of its total supplier spend, totaling $695,336,854. By August 2023, Bristol Myers Squibb had invested over $1 billion with diverse-owned suppliers, contracting with more than 600 such suppliers, achieving this milestone ahead of its 2025 target.

Honest & Fair Business

Bristol-Myers Squibb incurred significant ethics-related regulatory penalties totaling $1.616 billion in the past three years.

This includes a $700 million settlement and a $916 million judge's order in Hawaii for failing to warn about Plavix's reduced effectiveness for certain ancestries. The company has a comprehensive anti-corruption program that prohibits bribery, kickbacks, improper payments, and facilitation payments globally, adhering to international laws such as the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act. This program includes written procedures, senior management commitment, risk assessments, mandatory training for employees and third-party representatives, regular auditing, and due diligence and monitoring for third parties. An inaugural report on its anti-corruption compliance program has been published, and the company is a signatory to the UN Global Compact. Bristol-Myers Squibb also provides a confidential, 24/7 Integrity Line for reporting suspected misconduct and prohibits retaliation against whistleblowers, with mandatory training for employees and third parties.

Kind to Animals

Bristol-Myers Squibb's animal testing policy adheres to the 3Rs principles (replacement, reduction, and refinement)

and requires compliance with applicable laws and internal directives . The company states it is committed to reducing reliance on animal testing and promoting non-animal models . It has committed to using synthetic alternatives to LAL reagents for new medicines in its development pipeline and is transitioning water testing at manufacturing sites to synthetic reagents . In June 2019, it partnered with Draper to develop a liver tissue model for drug toxicity screening . The company ceased the use of the forced swim test in January 2020 . However, its policy indicates that legal mandates can override the use of alternatives, and it still uses animals when required. Between 2013 and 2015, approximately 9,000 animals were used in testing, including over 1,700 dogs and 4,380 primates . In 2013, Bristol-Myers Squibb was fined $2,625 by the U.S. Department of Agriculture for Animal Welfare Act violations following the deaths of two monkeys . In 2026, two macaques died at its New Jersey testing facilities due to neglect . The company is not involved in animal agriculture .

No War, No Weapons

Bristol-Myers Squibb (BMS) is a biopharmaceutical company with no revenue from arms or defense contracts, explicitly rejecting militaristic affiliations.

As such, it has no defense business for its board to oversee, no exposure to controversial weapons, and no need for weapons-related ethical red lines, dual-use technology screening, or war-risk audits. The company is not subject to the Arms Trade Treaty and has no involvement in surveillance or intelligence activities. BMS is committed to respecting human rights, aligning with the UN Guiding Principles on Business and Human Rights, and has submitted annual Communications of Progress to the UN Global Compact for the last 10 years. In its supply chain, BMS prohibits forced, bonded, enslaved, indentured, or involuntary prison labor and human trafficking. Its 3P Standards, revised in 2024, require suppliers to uphold human rights principles, and its Responsible Sourcing Program leverages EcoVadis to assess suppliers on labor and human rights. The company's lobbying activities are in the Pharmaceuticals/Health Products industry, with no defense-related lobbying.

Planet-Friendly Business

Total Scope 1, 2, and 3 greenhouse gas emissions were 2.118 million tCO₂e in 2023, reflecting a 1.14% year-over-year decline from 2022.

The company has SBTi-validated near-term and net-zero targets, aiming for a 54.6% reduction in Scope 1, 2, and fuel/energy-related Scope 3 GHG emissions by 2033, and net-zero across its value chain by 2050. Approximately 30% of key suppliers have approved science-based targets, with a goal to engage 75% of suppliers by emissions in setting science-based targets by 2028. Climate risk assessment includes physical and transition risks across more than 180 assets and multiple time horizons (2025, 2035, 2050), utilizing high-emissions and low-carbon economy scenarios, indicating partial alignment with TCFD recommendations.

Respect for Cultures & Communities

Bristol-Myers Squibb and Sanofi were ordered to pay over $916 million in May 2024

and settled for $700 million in May 2025 . These actions stemmed from allegations of failing to warn about the effectiveness of the drug Plavix in patients of East Asian and Pacific Island ancestry due to genetic factors . This indicates a reactive response to a significant incident impacting specific communities.

Safe & Smart Tech

The company experienced at least two data breaches within the past three years, including a MOVEit vulnerability breach in May 2023 that compromised employee data such as names and Social Security numbers

, and another data breach on December 10, 2024 . A class action lawsuit was also filed in June 2024 concerning a data breach . The 2023 breach was reported to the Montana Attorney General . These incidents indicate unauthorized data use. The company has established Principles for Responsible Artificial Intelligence, defining ethical standards , but details on implementation or oversight are not provided. Users have rights to access, correct, delete data, and opt-out of marketing communications , with deletion requests handled via email . The company implements a comprehensive global human risk management program, including annual cybersecurity training for employees and monthly cyber behavior snapshots and ratings . It has Binding Corporate Rules for GDPR compliance , states adherence to applicable data protection laws , and its 10-K filing summary reported no regulatory actions, violations, or fines . Data is collected and retained as long as necessary for stated purposes and in accordance with applicable laws .

Zero Waste & Sustainable Products

Bristol Myers Squibb achieved an 82% waste diversion rate in 2024.

The company has implemented numerous waste reduction initiatives, including a Green Labs Certification Program that expanded to 670 labs with 99.7% participation by 2022 , and refurbished or recycled over 40,000 IT units in 2024. For hazardous waste, 2,024 metric tons were generated in 2024 , with 91 metric tons recycled or reused. The company has a target to achieve zero waste to landfill by 2040. No waste disposal violations were mentioned in the provided articles. Bristol Myers Squibb provides patient resources for medication and sharps disposal through dedicated websites.